Single Source Procurement: MiSeqDx System Instrumentation

Pursuant to New York State Finance Law § 163.10(b), The New York State Department of Health is presenting the following summary of relevant circumstances, and material and substantial reasons why a competitive procurement was not feasible. The Illumina MiSeqDx Next-Generation Sequencing (NGS) platform and application is the only FDA approved NGS system for in-vitro use within a clinical laboratory.

Procurement / Program Name MiSeqDx System Instrumentation
Contractor Name(s) Illumina, Inc.
Contract Period One Time Purchase
Contract Numbers OP033560